Forgent Power Solutions Inc. Class A Common Stock vs Vaxcyte Inc. Common Stock — how do they compare? Forgent Power Solutions Inc. Class A Common Stock trades at $32.19 (market cap $9.93B), while Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B). The key difference: Forgent Power Solutions Inc. Class A Common Stock and Vaxcyte Inc. Common Stock are close in size by market cap, and Vaxcyte Inc. Common Stock is trading nearer its 52-week high, Forgent Power Solutions Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Forgent Power Solutions Inc. Class A Common Stock for 0 Days and Vaxcyte Inc. Common Stock for 0 Days on average.
| FPS | PCVX | |
|---|---|---|
Market Cap | $9.93B | $10.51B |
Volume | 7,516,726 | 2,644,694 |
Sector | Industrials | Health |
52-Week High | $64.59 | $73.82 |
52-Week Low | $27.97 | $40.32 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $10.54B | $9.14B |
Signals from Pluang's Aura AI — not financial advice
Forgent Power Solutions (FPS) trades at $36.17, down 2.48% on the day, following a strong earnings-driven rally. The stock shows neutral technical signals with support at $35 and resistance at $37. Recent Q2 2026 earnings beat expectations with EPS of $0.25 versus $0.24 expected, continuing a pattern of quarterly outperformance. The company reported record $3 billion backlog and strong data center demand driving growth.
FPS presents significant upside potential with analyst consensus target of $55.20 (52.9% upside) and 85.7% buy ratings. However, high valuation multiples (P/E 120.57, P/S 6.21) and negative 2025 net income of -$6.17M create valuation concerns. Key risks include execution on $3B backlog and potential overvaluation amid AI infrastructure hype.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Forgent Power Solutions designs and manufactures electrical distribution equipment, including transformers, switchgear, transfer switches, and prefabricated power systems, for data centers, the power grid, and industrial facilities, manufacturing across multiple product categories in-house through a network of manufacturing campuses in US.
Read more on FPS →Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →